Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Karen A. Foster, the Chief Quality and Operations Officer at BioLife Solutions Inc. (NASDAQ:BLFS), recently sold 320 shares of the company’s common stock. The company, with a market capitalization of $1.1 billion, has demonstrated strong revenue growth of ~35% over the last twelve months. According to InvestingPro analysis, BLFS maintains a healthy financial position with a current ratio of 4.73, indicating strong liquidity. The transaction, which took place on June 10, 2025, was executed at a price of $23.70 per share, amounting to a total value of $7,584. Following this sale, Foster retains ownership of 194,996 shares. InvestingPro analysis suggests the stock is currently trading slightly above its Fair Value, with additional insights available in the comprehensive Pro Research Report. This transaction was conducted under a pre-established Rule 10b5-1 trading plan, intended to satisfy tax withholding obligations related to the vesting of restricted stock.
In other recent news, BioLife Solutions reported its first-quarter 2025 earnings, surpassing expectations with a revenue of $23.9 million, which exceeded the anticipated $21.6 million. The company’s earnings per share (EPS) also beat forecasts, coming in at -$0.01 compared to the expected -$0.05. This performance reflects a 30% year-over-year revenue increase, driven by a 33% growth in its cell processing platform. The adjusted EBITDA margin improved to 24%, indicating enhanced operational efficiency. Furthermore, BioLife Solutions has set its full-year revenue guidance between $95.5 million and $99 million, projecting 16-20% growth. In terms of analyst activity, H.C. Wainwright maintained a Buy rating for BioLife Solutions with a $30 price target, following discussions with the company’s management. The firm adjusted its quarterly revenue projections for 2025, excluding discontinued operations, but upheld its full-year revenue forecast of $97.5 million. These developments highlight a positive outlook for BioLife Solutions as it continues to expand its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.